Go Pro
→ There Are 2 Ways Into an IPO (From Weiss Ratings) (Ad)tc pixel Free APRE Stock Alerts

Aprea Therapeutics (APRE) Financials

Aprea Therapeutics logo
$0.79 -0.01 (-1.49%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Aprea Therapeutics

Annual Income Statements for Aprea Therapeutics

This table shows Aprea Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -16 -27 -52 -37 -113 -14 -13 -13
Consolidated Net Income / (Loss)		 -16 -28 -53 -37 -113 -14 -13 -13
Net Income / (Loss) Continuing Operations		 -16 -27 -53 -37 -112 -14 -13 -13
Total Pre-Tax Income 		-16 -28 -53 -37 -113 -14 -13 -13
Total Operating Income		 -16 -30 -53 -37 -113 -15 -14 -13
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.58 1.50 0.29
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.58 1.50 0.29
Operating Revenue		 - - - 0.00 0.00 0.58 1.50 0.29
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 16 30 53 37 113 16 16 14
Selling, General & Admin Expense		 2.29 8.59 15 14 21 8.43 6.46 6.48
Research & Development Expense		 14 21 38 24 92 7.63 9.36 7.04
Total Other Income / (Expense), net		 0.96 1.48 -0.67 0.32 0.73 1.19 1.36 0.63
Interest & Investment Income		 -0.00 0.16 0.22 0.00 0.45 1.22 1.29 0.65
Other Income / (Expense), net		 0.96 1.33 -0.89 0.32 0.28 -0.04 0.07 -0.02
Basic Earnings per Share		 ($13.45) ($4.67) ($50.61) ($34.88) ($67.99) ($3.95) ($2.35) ($1.93)
Weighted Average Basic Shares Outstanding		 1.15M 6.00M 1.06M 1.06M 1.66M 3.62M 5.51M 6.54M
Diluted Earnings per Share		 ($13.45) ($4.67) ($50.61) ($34.88) ($67.99) ($3.95) ($2.35) ($1.93)
Weighted Average Diluted Shares Outstanding		 1.15M 6.00M 1.06M 1.06M 1.66M 3.62M 5.51M 6.54M
Weighted Average Basic & Diluted Shares Outstanding		 1.15M 6.00M 21.13M 21.97M 3.73M 5.43M 5.49M 11.45M

Quarterly Income Statements for Aprea Therapeutics

This table shows Aprea Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.44 -2.81 -3.47 -3.78 -2.89 -3.93 -3.24 -2.97 -2.46 -3.29 -3.59
Consolidated Net Income / (Loss)		 -3.44 -2.81 -3.47 -3.78 -2.89 -3.93 -3.24 -2.97 -2.46 -3.29 -3.59
Net Income / (Loss) Continuing Operations		 -3.44 -2.81 -3.47 -3.78 -2.89 -3.93 -3.24 -2.97 -2.46 -3.29 -3.59
Total Pre-Tax Income 		-3.44 -2.81 -3.47 -3.78 -2.89 -3.93 -3.24 -2.97 -2.46 -3.29 -3.59
Total Operating Income		 -3.67 -3.15 -3.85 -4.10 -3.23 -4.09 -3.39 -3.12 -2.64 -3.43 -4.03
Total Gross Profit		 0.01 0.38 0.56 0.35 0.21 0.16 0.12 0.00 0.00 0.00 0.00
Total Revenue		 0.01 0.38 0.56 0.35 0.21 0.16 0.12 0.00 0.00 0.00 0.00
Operating Revenue		 0.01 0.38 0.56 0.35 0.21 0.16 0.12 0.00 0.00 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 3.69 3.53 4.41 4.45 3.43 4.25 3.51 3.12 2.65 3.43 4.03
Selling, General & Admin Expense		 1.64 1.93 1.85 1.61 1.07 1.76 1.59 1.48 1.64 1.82 1.57
Research & Development Expense		 2.05 1.60 2.56 2.85 2.36 2.48 1.91 1.64 1.01 1.61 2.46
Total Other Income / (Expense), net		 0.23 0.34 0.38 0.31 0.33 0.15 0.15 0.14 0.19 0.14 0.44
Interest & Investment Income		 0.31 0.28 0.38 0.35 0.27 0.20 0.18 0.15 0.12 0.13 0.36
Other Income / (Expense), net		 -0.08 0.06 -0.01 -0.04 0.06 -0.05 -0.03 -0.01 0.07 0.01 0.08
Basic Earnings per Share		 ($0.95) ($0.67) ($0.58) ($0.64) ($0.53) ($0.66) ($0.53) ($0.47) ($0.27) ($0.22) ($0.07)
Weighted Average Basic Shares Outstanding		 3.62M 4.20M 5.94M 5.94M 5.51M 5.99M 6.08M 6.37M 6.54M 14.69M 53.48M
Diluted Earnings per Share		 ($0.95) ($0.67) ($0.58) ($0.64) ($0.53) ($0.66) ($0.53) ($0.47) ($0.27) ($0.22) ($0.07)
Weighted Average Diluted Shares Outstanding		 3.62M 4.20M 5.94M 5.94M 5.51M 5.99M 6.08M 6.37M 6.54M 14.69M 53.48M
Weighted Average Basic & Diluted Shares Outstanding		 5.43M 5.43M 5.43M 5.43M 5.49M 5.53M 5.83M 6.31M 11.45M 12.38M 12.59M

Annual Cash Flow Statements for Aprea Therapeutics

This table details how cash moves in and out of Aprea Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 41 64 -42 -36 -24 -7.13 1.25 -8.25
Net Cash From Operating Activities		 -15 -27 -42 -38 -25 -12 -14 -13
Net Cash From Continuing Operating Activities		 -15 -27 -42 -38 -25 -12 -14 -13
Net Income / (Loss) Continuing Operations		 -16 -28 -53 -37 -113 -14 -13 -13
Consolidated Net Income / (Loss)		 -16 -28 -53 -37 -113 -14 -13 -13
Depreciation Expense		 0.01 0.01 0.03 0.01 0.00 0.01 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 -0.63 0.02 5.87 7.50 89 0.48 0.42 0.57
Changes in Operating Assets and Liabilities, net		 0.90 1.16 5.57 -8.33 -1.76 1.62 -1.06 -0.93
Net Cash From Investing Activities		 -0.00 -0.03 -0.03 0.00 0.00 -0.09 -0.02 0.00
Net Cash From Continuing Investing Activities		 -0.00 -0.03 -0.03 0.00 0.00 -0.09 -0.02 0.00
Purchase of Property, Plant & Equipment		 -0.00 -0.03 -0.03 0.00 0.00 -0.09 -0.02 0.00
Net Cash From Financing Activities		 56 93 0.15 1.75 0.68 5.14 15 4.64
Net Cash From Continuing Financing Activities		 56 93 0.15 1.75 0.68 5.14 15 4.64
Repurchase of Common Equity		 - - - 0.00 0.00 -0.65 -1.32 -0.41
Issuance of Common Equity		 0.00 87 0.00 1.54 0.68 5.79 16 5.05
Other Financing Activities, net		 0.00 0.07 0.15 0.21 0.00 - 0.00 0.00
Effect of Exchange Rate Changes		 - -1.42 - -0.00 - -0.01 -0.01 0.00

Quarterly Cash Flow Statements for Aprea Therapeutics

This table details how cash moves in and out of Aprea Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -3.75 11 -3.67 -2.47 -3.38 -3.58 -2.74 -2.81 0.88 32 -5.23
Net Cash From Operating Activities		 -3.74 -3.94 -3.64 -2.47 -3.51 -3.63 -3.13 -3.17 -2.96 -2.76 -3.28
Net Cash From Continuing Operating Activities		 -3.74 -3.94 -3.64 -2.47 -3.53 -3.63 -3.13 -3.17 -3.00 -2.76 -3.28
Net Income / (Loss) Continuing Operations		 -3.44 -2.81 -3.47 -3.78 -2.89 -3.93 -3.24 -2.97 -2.46 -3.29 -3.59
Consolidated Net Income / (Loss)		 -3.44 -2.81 -3.47 -3.78 -2.89 -3.93 -3.24 -2.97 -2.46 -3.29 -3.59
Depreciation Expense		 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.16 0.03 0.13 0.18 0.07 0.17 0.17 0.12 0.12 0.09 0.10
Changes in Operating Assets and Liabilities, net		 -0.46 -1.16 -0.31 1.13 -0.71 0.13 -0.06 -0.32 -0.67 0.43 0.21
Net Cash From Investing Activities		 -0.01 -0.01 -0.01 - - 0.00 - - - 0.00 -0.02
Net Cash From Continuing Investing Activities		 -0.01 -0.01 -0.01 - - 0.00 - - - 0.00 -0.02
Net Cash From Financing Activities		 - 15 -0.02 -0.00 0.13 0.06 0.38 0.36 3.84 35 -1.94
Net Cash From Continuing Financing Activities		 - 15 -0.02 -0.00 0.13 0.06 0.38 0.36 3.84 35 -1.94
Repurchase of Common Equity		 - -1.29 -0.02 -0.00 -0.01 -0.00 -0.01 -0.02 -0.37 -0.47 -2.44
Issuance of Common Equity		 - 16 - - 0.14 0.06 0.40 0.38 4.21 35 0.50

Annual Balance Sheets for Aprea Therapeutics

This table presents Aprea Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 66 134 93 57 30 23 24 16
Total Current Assets		 66 133 92 57 30 23 24 16
Cash & Equivalents		 66 130 89 53 29 22 23 15
Prepaid Expenses		 0.32 2.96 3.40 3.51 1.37 0.91 0.73 0.96
Plant, Property, & Equipment, net		 0.02 0.04 0.04 0.02 0.00 0.09 0.08 0.06
Total Noncurrent Assets		 0.00 0.52 0.35 0.22 0.00 0.04 0.32 0.31
Other Noncurrent Operating Assets		 0.00 0.52 0.35 0.22 0.00 0.04 0.32 0.31
Total Liabilities & Shareholders' Equity		 66 134 93 57 30 23 24 16
Total Liabilities		 4.87 9.36 15 7.32 3.20 4.39 3.36 2.76
Total Current Liabilities		 4.87 9.06 15 7.32 3.20 4.39 3.36 2.76
Accounts Payable		 1.74 2.18 4.50 1.77 0.84 1.67 1.35 0.71
Accrued Expenses		 3.13 6.64 11 5.35 2.36 2.19 2.01 2.05
Total Noncurrent Liabilities		 0.00 0.30 0.08 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 113 - - 0.00 1.31 1.31 1.31 0.73
Total Equity & Noncontrolling Interests		 -51 124 77 50 26 17 19 12
Total Preferred & Common Equity		 -51 124 77 50 26 17 19 12
Total Common Equity		 -51 124 77 50 26 17 19 12
Common Stock		 20 226 231 241 330 336 351 357
Retained Earnings		 -62 -91 -144 -181 -294 -308 -321 -334
Accumulated Other Comprehensive Income / (Loss)		 -8.76 -12 -10 -10 -11 -11 -11 -11

Quarterly Balance Sheets for Aprea Therapeutics

This table presents Aprea Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 26 33 30 27 20 17 14 48 42
Total Current Assets		 26 33 30 26 20 17 14 47 42
Cash & Equivalents		 25 32 29 26 19 17 14 46 41
Prepaid Expenses		 0.29 0.70 0.87 0.23 0.56 0.40 0.23 0.78 0.68
Plant, Property, & Equipment, net		 0.09 0.09 0.09 0.09 0.08 0.07 0.07 0.05 0.06
Total Noncurrent Assets		 0.04 0.04 0.31 0.32 0.31 0.31 0.31 0.31 0.31
Other Noncurrent Operating Assets		 0.04 0.04 0.31 0.32 0.31 0.31 0.31 0.31 0.31
Total Liabilities & Shareholders' Equity		 26 33 30 27 20 17 14 48 42
Total Liabilities		 4.17 2.97 3.09 3.64 3.36 3.17 2.68 5.30 3.09
Total Current Liabilities		 4.17 2.97 3.09 3.64 3.36 3.17 2.68 5.30 3.09
Accounts Payable		 0.86 1.32 0.96 1.15 1.28 1.20 0.64 2.94 0.94
Accrued Expenses		 3.30 1.50 2.08 2.48 2.08 1.97 2.04 2.36 2.16
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 1.31 1.31 1.31 1.31 1.31 0.73 0.73 0.73 0.73
Total Equity & Noncontrolling Interests		 20 29 26 22 16 13 11 42 38
Total Preferred & Common Equity		 20 29 26 22 16 13 11 42 38
Total Common Equity		 20 29 26 22 16 13 11 42 38
Common Stock		 336 350 351 351 351 352 353 389 390
Retained Earnings		 -305 -311 -314 -318 -325 -328 -331 -337 -341
Accumulated Other Comprehensive Income / (Loss)		 -11 -11 -11 -11 -11 -11 -11 -11 -11

Annual Metrics And Ratios for Aprea Therapeutics

This table displays calculated financial ratios and metrics derived from Aprea Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 20,990,502.00 21,186,827.00 21,465,140.00 52,997,814.00 3,736,673.00 5,434,903.00 6,310,673.00
DEI Adjusted Shares Outstanding		 0.00 1,049,525.00 1,059,341.00 1,073,257.00 2,649,891.00 3,736,673.00 5,434,903.00 6,310,673.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -25.32 -49.07 -34.59 -42.52 -3.82 -2.38 -2.00
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 157.63% -80.98%
EBITDA Growth		 0.00% -80.71% -90.66% 31.07% -206.38% 86.27% 8.25% 7.00%
EBIT Growth		 0.00% -81.71% -90.32% 30.86% -204.64% 86.29% 8.14% 6.99%
NOPAT Growth		 0.00% -79.17% -78.75% 29.09% -202.81% 86.36% 7.45% 7.58%
Net Income Growth		 0.00% -80.70% -90.59% 30.58% -203.45% 87.32% 9.30% 2.77%
EPS Growth		 0.00% 65.28% -90.59% 30.58% -203.45% 94.19% 40.51% 17.87%
Operating Cash Flow Growth		 0.00% -75.14% -56.51% 9.85% 33.63% 51.31% -11.33% 4.89%
Free Cash Flow Firm Growth		 0.00% 0.00% -61.13% -9.86% -136.71% 88.51% -19.47% 9.61%
Invested Capital Growth		 0.00% -29.28% -98.83% 69.29% 48.67% -82.45% 33.24% 35.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 2.47% 14.63% -41.47%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 17.23% 4.23% -7.35% 3.95% 4.30%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 17.10% 4.27% -7.40% 3.94% 4.30%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 14.59% 4.37% -7.08% 3.04% 4.22%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 17.06% 4.50% -7.54% 4.06% 3.37%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 17.06% 4.50% -11.58% -3.52% 5.85%
Operating Cash Flow Q/Q Growth		 0.00% -68.86% 3.56% 7.42% 19.76% 2.25% 1.66% 4.09%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 7.33% 5.38% -0.32% 4.92%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 55.46% 47.49% 10.95% 25.41% 31.16%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,658.27% -946.74% -4,629.75%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,652.80% -953.00% -4,631.12%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,659.48% -948.23% -4,637.35%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,449.59% -862.43% -4,409.16%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.45% 99.59% 100.00% 99.60% 92.11% 90.95% 95.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -25.39% -30.27% -53.04% -58.51% -294.69% -63.19% -66.65% -74.58%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -58.75% -61.11% -66.40%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -54.11% -55.58% -63.14%
Return on Common Equity (ROCE)		 21.36% -11.89% -53.04% -58.51% -289.64% -59.52% -62.16% -70.08%
Return on Equity Simple (ROE_SIMPLE)		 30.19% -22.58% -69.10% -74.99% -439.34% -84.27% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -21 -37 -26 -79 -11 -10 -9.26
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,856.96% -667.10% -3,241.78%
Net Nonoperating Expense Percent (NNEP)		 -6.07% -7.54% -15.07% -15.36% -81.33% -13.72% -13.20% -17.82%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -63.88% -51.92% -74.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,445.00% 429.84% 2,266.44%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,307.80% 623.16% 2,464.68%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2,752.80% 1,053.00% 4,731.12%
Earnings before Interest and Taxes (EBIT)		 -16 -28 -54 -37 -113 -16 -14 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -28 -53 -37 -113 -16 -14 -13
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 7.75 1.35 1.24 0.68 1.04 0.93 0.43
Price to Tangible Book Value (P/TBV)		 0.00 7.75 1.35 1.24 0.68 1.04 0.93 0.43
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 30.11 11.90 18.84
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.06 -1.09 -1.12 -1.07 -1.11 -1.14 -1.11
Leverage Ratio		 1.08 1.08 1.12 1.18 1.14 1.17 1.20 1.18
Compound Leverage Factor		 1.08 1.07 1.12 1.18 1.13 1.08 1.09 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 184.11% 0.00% 0.00% 0.00% 4.86% 7.18% 6.36% 5.52%
Common Equity to Total Capital		 -84.11% 100.00% 100.00% 100.00% 95.14% 92.82% 93.64% 94.48%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.49 61.19 0.97 -0.53 -21.66 -17.91 -16.44 -29.91
Noncontrolling Interest Sharing Ratio		 184.11% 60.73% 0.00% 0.00% 1.71% 5.80% 6.74% 6.03%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 13.56 14.68 6.03 7.73 9.42 5.14 7.01 5.63
Quick Ratio		 13.49 14.36 5.81 7.25 8.99 4.93 6.80 5.28
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -31 -34 -81 -9.32 -11 -10
Operating Cash Flow to CapEx		 -411,945.81% -86,433.15% -162,599.37% 0.00% 0.00% -13,081.12% -87,587.01% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.02 0.06 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 12.86 17.69 4.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -4.52 -5.85 -12 -3.57 -1.83 -3.34 -2.23 -1.43
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.23 -0.54 -0.16
Increase / (Decrease) in Invested Capital		 0.00 -1.32 -5.78 8.05 1.74 -1.51 1.11 0.80
Enterprise Value (EV)		 132 833 15 8.53 -9.93 -2.73 -3.66 -8.49
Market Capitalization		 85 963 104 62 18 18 18 5.38
Book Value per Share		 ($44.56) $5.92 $3.65 $2.31 $0.48 $4.54 $3.55 $1.97
Tangible Book Value per Share		 ($44.56) $5.92 $3.65 $2.31 $0.48 $4.54 $3.55 $1.97
Total Capital		 61 124 77 50 27 18 21 13
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -66 -130 -89 -53 -29 -22 -23 -15
Capital Expenditures (CapEx)		 0.00 0.03 0.03 0.00 0.00 0.09 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.55 -6.11 -12 -3.81 -1.83 -3.47 -2.63 -1.80
Debt-free Net Working Capital (DFNWC)		 61 124 77 49 27 18 20 13
Net Working Capital (NWC)		 61 124 77 49 27 18 20 13
Net Nonoperating Expense (NNE)		 3.99 7.38 17 11 33 3.46 2.93 3.34
Net Nonoperating Obligations (NNO)		 -66 -130 -89 -53 -29 -22 -23 -15
Total Depreciation and Amortization (D&A)		 0.01 0.17 0.23 0.27 0.19 0.01 0.02 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -595.19% -175.35% -630.76%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 3,109.49% 1,345.36% 4,478.21%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 3,109.49% 1,345.36% 4,478.21%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($50.60) ($34.80) ($67.99) ($3.95) ($2.35) ($1.93)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 1.06M 1.06M 1.66M 3.62M 5.51M 6.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($50.60) ($34.80) ($68.16) ($3.95) ($2.45) ($1.93)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 1.06M 1.06M 1.66M 3.62M 5.51M 6.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($50.60) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 1.06M 1.10M 3.73M 5.43M 5.49M 11.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -21 -37 -26 -79 -11 -10 -9.26
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,856.96% -667.10% -3,241.78%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -2,449.59% -862.43% -4,409.16%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -4.54% -10.17% -3.23%

Quarterly Metrics And Ratios for Aprea Therapeutics

This table displays calculated financial ratios and metrics derived from Aprea Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 3,736,673.00 5,430,215.00 5,430,215.00 5,431,903.00 5,434,903.00 5,491,953.00 5,531,373.00 5,825,261.00 6,310,673.00 11,452,452.00 12,382,776.00
DEI Adjusted Shares Outstanding		 3,736,673.00 5,430,215.00 5,430,215.00 5,431,903.00 5,434,903.00 5,491,953.00 5,531,373.00 5,825,261.00 6,310,673.00 11,452,452.00 12,382,776.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.92 -0.52 -0.64 -0.70 -0.53 -0.72 -0.59 -0.51 -0.39 -0.29 -0.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 124.91% 11.00% 1,362.29% -57.31% -78.97% -99.48% -98.38% -100.00% -100.00%
EBITDA Growth		 -39.48% 33.40% -7.01% -17.10% 15.59% -33.84% 11.32% 24.46% 18.81% 17.30% -15.62%
EBIT Growth		 -39.79% 33.28% -7.15% -17.21% 15.56% -33.74% 11.31% 24.43% 18.78% 17.27% -15.61%
NOPAT Growth		 -38.59% 31.86% -5.35% -16.30% 12.21% -29.71% 11.94% 23.91% 18.07% 16.04% -19.02%
Net Income Growth		 -40.99% 35.84% -6.47% -18.08% 15.93% -39.95% 6.66% 21.44% 15.17% 16.39% -10.88%
EPS Growth		 33.57% 50.00% 33.33% 25.58% 44.21% 1.49% 8.62% 26.56% 49.06% 66.67% 86.79%
Operating Cash Flow Growth		 6.99% -32.12% -13.20% -10.10% 6.12% 7.74% 14.03% -28.48% 15.65% 24.08% -4.73%
Free Cash Flow Firm Growth		 70.44% 20.11% 32.49% -64.85% -217.21% 21.15% 52.78% 14.70% 21.31% 74.21% -75.94%
Invested Capital Growth		 -82.45% 33.34% 38.27% 20.29% 33.24% -13.10% -31.02% 30.54% 35.90% -71.88% 14.83%
Revenue Q/Q Growth		 -95.59% 2,603.87% 47.56% -36.85% -41.96% -21.06% -27.30% -98.44% 80.57% -100.00% 0.00%
EBITDA Q/Q Growth		 -6.36% 17.64% -24.61% -7.28% 23.34% -30.59% 17.44% 8.61% 17.60% -33.03% -15.43%
EBIT Q/Q Growth		 -6.46% 17.58% -24.53% -7.27% 23.31% -30.54% 17.41% 8.60% 17.57% -32.96% -15.41%
NOPAT Q/Q Growth		 -4.32% 14.29% -22.14% -6.50% 21.26% -26.64% 17.08% 7.98% 15.21% -29.79% -17.54%
Net Income Q/Q Growth		 -7.45% 18.39% -23.49% -9.04% 23.49% -35.85% 17.64% 8.23% 17.39% -33.89% -9.23%
EPS Q/Q Growth		 -10.47% 29.47% 13.43% -10.34% 17.19% -24.53% 19.70% 11.32% 42.55% 18.52% 68.18%
Operating Cash Flow Q/Q Growth		 -66.80% -5.25% 7.48% 32.22% -42.24% -3.43% 13.78% -1.29% 6.62% 6.91% -18.94%
Free Cash Flow Firm Q/Q Growth		 51.76% -208.10% -16.85% 5.08% 7.17% 23.42% 30.02% -71.46% 14.36% 74.90% -377.32%
Invested Capital Q/Q Growth		 10.95% 36.12% 14.55% -63.98% 25.41% -8.22% 1.02% 13.07% 31.16% -190.18% 50.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -26,632.72% -811.24% -685.06% -1,163.80% -1,537.29% -2,543.32% -2,888.36% -168,704.00% -76,981.27% 0.00% 0.00%
Operating Margin		 -26,109.62% -827.62% -685.03% -1,155.32% -1,567.43% -2,514.78% -2,868.30% -168,689.83% -79,205.66% 0.00% 0.00%
EBIT Margin		 -26,668.14% -812.86% -686.01% -1,165.33% -1,539.92% -2,546.66% -2,892.95% -168,997.78% -77,143.96% 0.00% 0.00%
Profit (Net Income) Margin		 -24,463.62% -738.39% -617.92% -1,066.99% -1,406.49% -2,420.65% -2,742.23% -160,844.70% -73,587.95% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 91.73% 90.84% 90.07% 91.56% 91.34% 95.05% 94.79% 95.18% 95.39% 96.06% 90.91%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -63.19% -43.83% -50.11% -60.22% -66.65% -59.80% -67.54% -74.72% -74.58% -40.40% -46.15%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -589.09% -24.02% -29.84% -58.02% -99.24% -122.46% -102.93% -4,003.92% -1,104.63% 0.00% 0.00%
Return on Assets (ROA)		 -540.39% -21.82% -26.88% -53.12% -90.64% -116.40% -97.57% -3,810.75% -1,053.72% 0.00% 0.00%
Return on Common Equity (ROCE)		 -59.52% -41.85% -47.56% -56.70% -62.16% -56.47% -64.18% -70.36% -70.08% -39.01% -44.89%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -43.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.57 -2.20 -2.69 -2.87 -2.26 -2.86 -2.37 -2.18 -1.85 -2.40 -2.82
NOPAT Margin		 -18,276.73% -579.33% -479.52% -808.73% -1,097.20% -1,760.34% -2,007.81% -118,082.88% -55,443.96% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.46% -1.91% -2.76% -3.55% -2.86% -4.15% -3.84% -3.95% -3.23% -2.70% -2.66%
Return On Investment Capital (ROIC_SIMPLE)		 -15.17% -7.62% -10.54% -13.07% -11.70% -18.39% -17.68% -20.00% -14.87% -5.77% -7.34%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 11,675.42% 507.10% 329.58% 452.66% 521.23% 1,086.39% 1,349.30% 80,103.84% 49,073.75% 0.00% 0.00%
R&D to Revenue		 14,534.20% 420.52% 455.45% 802.66% 1,146.21% 1,528.39% 1,619.00% 88,685.98% 30,231.91% 0.00% 0.00%
Operating Expenses to Revenue		 26,209.62% 927.62% 785.03% 1,255.32% 1,667.43% 2,614.78% 2,968.30% 168,789.83% 79,305.66% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.75 -3.09 -3.85 -4.13 -3.17 -4.14 -3.42 -3.12 -2.57 -3.42 -3.95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.75 -3.09 -3.85 -4.13 -3.16 -4.13 -3.41 -3.12 -2.57 -3.42 -3.94
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.04 1.26 0.86 0.68 0.93 0.72 0.70 0.79 0.43 0.21 0.26
Price to Tangible Book Value (P/TBV)		 1.04 1.26 0.86 0.68 0.93 0.72 0.70 0.79 0.43 0.21 0.26
Price to Revenue (P/Rev)		 30.11 37.69 17.32 11.40 11.90 8.72 11.12 17.60 18.84 70.86 1,916.05
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 5.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.11 -1.09 -1.09 -1.15 -1.14 -1.10 -1.10 -1.15 -1.11 -1.11 -1.08
Leverage Ratio		 1.17 1.12 1.14 1.17 1.20 1.13 1.15 1.18 1.18 1.15 1.12
Compound Leverage Factor		 1.07 1.02 1.02 1.07 1.10 1.08 1.09 1.12 1.13 1.10 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 7.18% 4.34% 4.88% 5.64% 6.36% 7.78% 5.14% 6.25% 5.52% 1.72% 1.86%
Common Equity to Total Capital		 92.82% 95.66% 95.12% 94.36% 93.64% 92.22% 94.86% 93.75% 94.48% 98.28% 98.14%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -16.20 -4.95 -9.72 -13.54 -14.91 -20.13 -24.42 -30.19 -27.70 -8.09 -8.55
Noncontrolling Interest Sharing Ratio		 5.80% 4.52% 5.08% 5.85% 6.74% 5.57% 4.97% 5.84% 6.03% 3.44% 2.73%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.14 11.15 9.55 7.28 7.01 5.90 5.34 5.20 5.63 8.92 13.55
Quick Ratio		 4.93 10.92 9.27 7.22 6.80 5.73 5.22 5.12 5.28 8.77 13.33
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.06 -3.27 -3.82 -3.63 -3.37 -2.58 -1.81 -3.10 -2.65 -0.67 -3.18
Operating Cash Flow to CapEx		 -52,302.91% -49,334.31% -48,554.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.03 0.04 0.05 0.06 0.05 0.04 0.02 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 12.86 20.93 27.12 15.14 17.69 15.45 10.32 6.42 4.04 1.89 0.08
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.34 -2.14 -1.82 -2.99 -2.23 -2.41 -2.39 -2.08 -1.43 -4.15 -2.04
Invested Capital Turnover		 -0.23 -0.36 -0.53 -0.39 -0.54 -0.56 -0.40 -0.19 -0.16 -0.04 0.00
Increase / (Decrease) in Invested Capital		 -1.51 1.07 1.13 0.76 1.11 -0.28 -0.57 0.91 0.80 -1.74 0.35
Enterprise Value (EV)		 -2.73 5.27 -5.28 -10 -3.66 -6.76 -6.46 -4.40 -8.49 -37 -31
Market Capitalization		 18 36 22 15 18 11 9.35 8.59 5.38 8.74 9.93
Book Value per Share		 $4.54 $5.33 $4.71 $4.04 $3.55 $2.83 $2.43 $1.87 $1.97 $3.63 $3.11
Tangible Book Value per Share		 $4.54 $5.33 $4.71 $4.04 $3.55 $2.83 $2.43 $1.87 $1.97 $3.63 $3.11
Total Capital		 18 30 27 23 21 17 14 12 13 42 39
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -22 -32 -29 -26 -23 -19 -17 -14 -15 -46 -41
Capital Expenditures (CapEx)		 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.47 -2.27 -2.23 -3.40 -2.63 -2.80 -2.77 -2.46 -1.80 -4.52 -2.41
Debt-free Net Working Capital (DFNWC)		 18 30 26 23 20 16 14 11 13 42 39
Net Working Capital (NWC)		 18 30 26 23 20 16 14 11 13 42 39
Net Nonoperating Expense (NNE)		 0.87 0.61 0.78 0.92 0.64 1.07 0.87 0.79 0.61 0.89 0.77
Net Nonoperating Obligations (NNO)		 -22 -32 -29 -26 -23 -19 -17 -14 -15 -46 -41
Total Depreciation and Amortization (D&A)		 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -595.19% -235.13% -174.74% -259.51% -175.35% -218.18% -329.68% -502.86% -630.76% -3,663.87% -46,530.68%
Debt-free Net Working Capital to Revenue		 3,109.49% 3,123.44% 2,074.61% 1,743.00% 1,345.36% 1,282.49% 1,636.07% 2,306.84% 4,478.21% 34,022.83% 748,713.83%
Net Working Capital to Revenue		 3,109.49% 3,123.44% 2,074.61% 1,743.00% 1,345.36% 1,282.49% 1,636.07% 2,306.84% 4,478.21% 34,022.83% 748,713.83%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.95) ($0.67) ($0.58) ($0.64) ($0.53) ($0.66) ($0.53) ($0.47) ($0.27) ($0.22) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 3.62M 4.20M 5.94M 5.94M 5.51M 5.99M 6.08M 6.37M 6.54M 14.69M 53.48M
Adjusted Diluted Earnings per Share		 ($0.95) ($0.67) ($0.58) ($0.64) ($0.53) ($0.66) ($0.53) ($0.47) ($0.27) ($0.22) ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 3.62M 4.20M 5.94M 5.94M 5.51M 5.99M 6.08M 6.37M 6.54M 14.69M 53.48M
Adjusted Basic & Diluted Earnings per Share		 ($0.95) $0.00 $0.00 $0.00 ($0.53) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.43M 5.43M 5.43M 5.43M 5.49M 5.53M 5.83M 6.31M 11.45M 12.38M 12.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.57 -2.20 -2.69 -2.87 -2.26 -2.86 -2.37 -2.18 -1.85 -2.40 -2.82
Normalized NOPAT Margin		 -18,276.73% -579.33% -479.52% -808.73% -1,097.20% -1,760.34% -2,007.81% -118,082.88% -55,443.96% 0.00% 0.00%
Pre Tax Income Margin		 -24,463.62% -738.39% -617.92% -1,066.99% -1,406.49% -2,420.65% -2,742.23% -160,844.70% -73,587.95% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -4.54% -10.14% -10.14% -9.71% -10.17% -0.23% -0.19% -0.32% -3.23% -7.35% -26.83%

Financials Breakdown Chart

Key Financial Trends

Aprea Therapeutics’ financial statements show a cash-rich but unprofitable development-stage company. Revenue has declined sharply across the reported periods, while the company continues to fund research and administrative operations primarily through equity financing and its cash reserves.

Liquidity remains the strongest aspect of the balance sheet. Aprea held $41.2 million in cash and equivalents as of June 30, 2026, compared with $13.7 million at September 30, 2025 and $25.4 million at September 30, 2023. Current assets of $41.9 million substantially exceeded current liabilities of $3.1 million, and the company reported no noncurrent liabilities. Based on second-quarter operating cash usage of approximately $3.3 million, the cash balance represents roughly 12 quarters of operating funding before considering changes in spending, financing or investment income.

However, the cash increase has been driven largely by equity issuance rather than operations. Aprea raised $35.1 million through common equity issuance in the first quarter of 2026, following smaller equity raises in prior periods. In the second quarter, financing activity turned negative because the company repurchased $2.4 million of common equity while issuing only $0.5 million.

The income statement continues to reflect a biotechnology company without meaningful commercial revenue. Revenue fell from $561,574 in the second quarter of 2024 to $118,111 in the second quarter of 2025, and was zero in both the first and second quarters of 2026. Net losses remained substantial, at $3.6 million in the latest quarter, while research and development spending increased sequentially to $2.5 million.

  • Strong liquidity: Cash and equivalents totaled $41.2 million at June 30, 2026, providing a substantial funding cushion relative to the company’s quarterly operating burn.
  • Manageable balance-sheet obligations: Current liabilities declined to $3.1 million in Q2 2026 from $5.3 million in Q1 2026, and Aprea reported no noncurrent liabilities.
  • Improved near-term operating cash flow versus early 2025: Quarterly operating cash outflow was $3.3 million in Q2 2026, compared with $3.6 million in Q1 2025 and $3.7 million in Q4 2023.
  • Research investment remains active: Research and development expense rose to $2.5 million in Q2 2026 from $1.6 million in Q1 2026, which may support advancement of the company’s pipeline if development efforts are successful.
  • Cash growth depends on financing: Cash increased significantly from late 2025 after Aprea raised $35.1 million through common equity issuance in Q1 2026, rather than through internally generated cash.
  • Interest income provides some support: Interest and investment income increased to $358,923 in Q2 2026 from $134,784 in Q1 2026, partially offsetting operating losses but not replacing recurring revenue.
  • No reported revenue in the latest two quarters: Operating revenue fell from $561,574 in Q2 2024 to $118,111 in Q2 2025 and then to zero in Q1 and Q2 2026.
  • Persistent operating losses: Aprea has reported net losses in every period provided, including a $3.6 million loss in Q2 2026 and a $3.3 million loss in Q1 2026.
  • Continued negative operating cash flow: Operating activities consumed $3.3 million in Q2 2026, extending a multi-year pattern of quarterly cash burn.
  • Equity dilution risk: The large Q1 2026 equity issuance increased the weighted-average basic share count to 14.7 million in Q1 and 53.5 million in Q2, while future funding needs could require additional share issuance.

For investors, the key issue is whether Aprea can convert its research spending and cash runway into clinical or commercial progress before additional capital is required. The balance sheet currently reduces near-term solvency risk, but the lack of revenue, recurring losses and reliance on equity financing remain significant risks to shareholder returns.

09/04/26 09:12 PM ETAI Generated. May Contain Errors.

Aprea Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aprea Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Aprea Therapeutics' net income appears to be on a downward trend, with a most recent value of -$12.60 million in 2025, falling from -$15.53 million in 2018. The previous period was -$12.96 million in 2024. Find out what analysts predict for Aprea Therapeutics in the coming months.

Aprea Therapeutics' total operating income in 2025 was -$13.23 million, based on the following breakdown:
  • Total Gross Profit: $285.76 thousand
  • Total Operating Expenses: $13.52 million

Over the last 7 years, Aprea Therapeutics' total revenue changed from $0.00 in 2018 to $285.76 thousand in 2025, a change of 28,575,900.0%.

Aprea Therapeutics' total liabilities were at $2.76 million at the end of 2025, a 17.8% decrease from 2024, and a 43.2% decrease since 2018.

In the past 7 years, Aprea Therapeutics' cash and equivalents has ranged from $14.60 million in 2025 to $130.09 million in 2019, and is currently $14.60 million as of their latest financial filing in 2025.

Over the last 7 years, Aprea Therapeutics' book value per share changed from -44.56 in 2018 to 1.97 in 2025, a change of -104.4%.


Related Companies

Financial statements for NASDAQ:APRE last updated on 8/24/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump’s “new Petrodollar” exposed
Trump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...
Porter & Company | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Man Who Called SpaceX Rise Says Elon’s NEW Project is Even Bigger
James Altucher called the rise of Nvidia, Apple, and SpaceX years before the crowd. Now he says he has uncover...
Paradigm Press | Sponsoredtc pixel
Half the market is standing on a trapdoor
Nearly half the value of the US stock market now sits in AI stocks - the most concentrated the market has been...
Behind the Markets | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
This Overlooked Fund Turns AI Stocks Into Weekly Income
A small fund pays investors weekly income from AI stocks that don't pay dividends on their own. Chief Incom...
Investors Alley | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel